Is tirzepatide a dual agonist — and why does it matter?

What does 'dual agonist' actually mean?

An agonist is a molecule that binds to a receptor and switches it on. Most GLP-1 medicines work by mimicking one gut hormone (GLP-1) which the gut releases after eating. GLP-1 signals fullness to the brain, slows how quickly food leaves the stomach, and helps regulate insulin release.

Tirzepatide does all of that, but it also mimics a second gut hormone: GIP. GIP is released even earlier in the digestive process and works through a separate receptor. When both receptors are activated together, the appetite-suppressing signal reaching the brain is broader and, in trials, more pronounced than GLP-1 stimulation alone.

A useful way to think about it: GLP-1 medicines send one signal; tirzepatide sends two. The role of GIP in tirzepatide's mechanism is still an active area of research, but the clinical outcome data from the SURMOUNT programme is clear. You can read more about the dual-action profile of tirzepatide and how it compares to single-agonist options if you want the deeper pharmacology.

One practical consequence: because the two hormones act through distinct cellular pathways, combining them does not simply double the side-effect burden, the tolerability profile in trials remained GI-led (nausea, constipation, indigestion) and broadly comparable to GLP-1-only medicines, per the NHS tirzepatide medicines page.

How does this compare to semaglutide, is one mechanism better?

A question our prescribers hear most weeks is whether the dual mechanism automatically makes tirzepatide the stronger choice. The honest answer is: for most people in the trial data, yes, but medicine is never that simple.

Semaglutide 2.4mg (Wegovy) acts on GLP-1 receptors only. In the STEP 1 trial it produced around 15% average weight loss over 68 weeks, which is meaningful. Tirzepatide at 15mg produced around 20–21% over a comparable period in SURMOUNT-1. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, confirmed that tirzepatide produced greater average weight loss than semaglutide 2.4mg directly.

That said, the right medicine for a given person depends on their medical history, any other conditions they have, how they tolerate each treatment, and which a prescriber judges appropriate after reviewing the full picture. Tirzepatide's dual status looks impressive on paper; whether it translates to the better outcome for you is a clinical conversation, not a web-page verdict.

For a broader look at the GLP-1 side of tirzepatide's mechanism, that page covers the single-pathway context in detail.

Does the dual mechanism change how tirzepatide is taken or licensed?

Not in the way you might expect. Tirzepatide is still a once-weekly subcutaneous injection, delivered via a pre-filled KwikPen. Each pen contains four weekly doses; injection sites rotate between the abdomen, thigh, and upper arm. The schedule starts at 2.5mg (a tolerability dose that lets the body adjust) and is stepped up by the prescriber, typically at four-week intervals, through strengths of 5, 7.5, 10, 12.5, and up to 15mg.

The UK licence, granted by the MHRA, covers weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. NICE's appraisal of tirzepatide (TA1026) recommends it within the NHS for adults with BMI 35 and at least one comorbidity, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance. Private prescribing follows the licensed criteria, which are broader than NICE's NHS recommendation.

The dual agonist label also carries a practical implication for certain patients: because tirzepatide may slow gastric absorption, women taking oral contraceptives are advised to add a barrier method for the first four weeks of treatment and for four weeks after each dose increase. A prescriber will cover this and any other relevant interactions during assessment. Storage follows standard refrigeration requirements, the SmPC, available on the eMC, has the exact detail. More on what tirzepatide is and how it works sits on the tirzepatide overview page.

Who makes tirzepatide and what is it sold as in the UK?

Tirzepatide is manufactured by Eli Lilly and sold in the UK under the brand name Mounjaro. In the United States it is also sold as Zepbound for weight loss, but that brand name does not exist as a UK product, Mounjaro is the only licensed UK presentation.

It carries a Black Triangle (▼) designation, which means it is subject to additional monitoring by the MHRA while longer-term real-world safety data accumulates. That is routine for newer medicines and does not indicate a particular concern. Patients and healthcare professionals can report any suspected side effects through the Yellow Card scheme.

For context on the relationship between tirzepatide and Mounjaro, including why some people search for one name and find the other, that page explains the brand-versus-molecule distinction clearly. If you are weighing up whether treatment might suit you, the weight-loss treatment overview sets out the options, and our free consultation is the place to put the question to a prescriber directly.